Decorporation of Radionuclides

Andersen, Ole

doi:10.1016/b978-0-12-803072-1.00005-5

Cited by 2 publications

(1 citation statement)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This work aimed to assess if patent metrics is a valuable tool for identifying and measuring the emergent technetium-99m technological innovations in the field of Nuclear Medicine. The method of analyzing healthcare technology that has been applied was inspired by previous publications, both in the field of radiopharmacy and in other medical disciplines, in order to validate and quantitatively–qualitatively evaluate the disclosed inventions as a marker for innovation in healthcare. ,, Furthermore, in the applied methodology, other relevant features (such as the patent owners, firms, and country) were qualitatively analyzed for each patent by the authors, to better appreciate the value the market potentially gives to technetium-99m technologies.…”

Section: Resultsmentioning

confidence: 99%

Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000–2022)

Riondato

Rigamonti²,

Martini

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

Technetium-99m is the workhorse of diagnostic nuclear medicine. The aim of the work is to analyze the technetium-99m patents since 2000 to photograph its innovation. QUESTEL’s ORBIT Intelligence system was used for the collection of technetium inventions disclosed in patents and patent applications in more than 96 countries in the period 2000–2022; 2768 patent documents were analyzed. Patent counting and analysis have shown that SPECT imaging using technetium-99m radiopharmaceuticals is still robust. The introduction of new technetium-99m radiopharmaceuticals into clinical routine goes beyond successful trials. In eastern economies, such as China and other emerging markets, patent applications are on the rise, while those in developed western countries are stagnating, with some exceptions for the United States. But despite the difficulties, academic and industrial research on these tracers remains essential for the development of nuclear medicine.

show abstract

Section: Resultsmentioning

confidence: 99%